Results 21 to 30 of about 21,749 (235)

Neuregulin-1β, Biomarkers of Inflammation and Myocardial Fibrosis in Heart Failure Patients

open access: yesРациональная фармакотерапия в кардиологии, 2022
Neuregulin-1β (NRG-1) is an emerging biomarker of heart failure (HF). The mechanisms of its action in HF patients are yet  to be investigated. Cardioprotective and anti-inflammatory  effects of NRG-1 have been reported.Aim.
K. A. Zhbanov   +7 more
doaj   +1 more source

Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches

open access: yesРациональная фармакотерапия в кардиологии, 2021
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago.
A. A. Shchendrygina   +9 more
doaj   +1 more source

Aortic flow is abnormal in HFpEF [PDF]

open access: yesWellcome Open Research, 2023
Aims Turbulent aortic flow makes the cardiovascular system less effective. It remains unknown if patients with heart failure with preserved ejection fraction (HFpEF) have disturbed aortic flow. This study sought to investigate advanced markers of aortic flow disturbances in HFpEF.
Mehmood, Z.   +18 more
openaire   +5 more sources

STEP-HFpEF: A Large Step for HFpEF. [PDF]

open access: yesJournal of the American College of Cardiology
Contains fulltext : 307714.pdf (Publisher’s version ) (Open Access)
Kimmenade, R.R.J. van, Hassing, C.
openaire   +3 more sources

Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options

open access: yesМедицинский вестник Юга России, 2021
Type 2 diabetes mellitus is known to increase the risk of the development of heart failure with preserved ejection fraction and worsen its symptoms. To date, no specific treatment has been shown to reduce morbidity and mortality in patients with heart ...
A. A. Borisov   +2 more
doaj   +1 more source

The Concept of "Heart Failure with Preserved Ejection Fraction": Time for a Critical Reappraisal

open access: yesReviews in Cardiovascular Medicine, 2023
Heart failure with preserved ejection fraction (HFpEF) is frequently observed in elderly physically deconditioned subjects, mainly women with hypertension, obesity, glucose intolerance/diabetes, atrial fibrillation, anaemia, coronary artery disease ...
Gabriele Fragasso
doaj   +1 more source

β-Hydroxybutyrate Mitigated Heart Failure with Preserved Ejection Fraction by Increasing Treg Cells via Nox2/GSK-3β

open access: yesJournal of Inflammation Research, 2021
Shengen Liao,1,* Yuan Tang,1,* Xin Yue,1 Rongrong Gao,1 Wenming Yao,1 Yanli Zhou,1 Haifeng Zhang2,3 1Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, People’s ...
Liao S   +6 more
doaj  

SGLT2 inhibitors: a new pillar of the heart failure regimen

open access: yesReviews in Cardiovascular Medicine, 2021
Initially intended as an adjunct treatment for type 2 diabetes mellitus (T2DM), SGLT2-inhibitors (SGLT2i) have transformed into an unexpected pillar of the heart failure (HF) regimen.
Travis DeSa   +1 more
doaj   +1 more source

Potential Mechanisms of Epicardial Adipose Tissue Influencing HeartFailure with Preserved Ejection Fraction

open access: yesReviews in Cardiovascular Medicine
Heart failure (HF) is the predominant terminal stage and the leading cause ofmortality in cardiac disease. Heart failure with preserved ejection fraction(HFpEF) affects roughly 50% of HF patients globally.
Qiuxuan Li   +5 more
doaj   +1 more source

Comparing the Diagnostic Performance of HFA-PEFF and H2FPEF Scoring Systems in Heart Failure with Preserved Ejection Fraction Patients: Insights from the APOLLON Registry

open access: yesAnatolian Journal of Cardiology, 2023
Background: Heart failure with preserved ejection fraction is a complex and heterogeneous clinical syndrome, poses significant diagnostic challenges.
Gurbet Özge Mert   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy